Preventive and curative glycoside kaempferol treatments attenuate the TH2-driven allergic airway disease


Autoria(s): MEDEIROS, K. C. P.; FAUSTINO, L.; BORDUCHI, E.; NASCIMENTO, R. J. B.; SILVA, T. M. S.; GOMES, E.; PIUVEZAM, M. R.; RUSSO, M.
Contribuinte(s)

UNIVERSIDADE DE SÃO PAULO

Data(s)

20/10/2012

20/10/2012

2009

Resumo

Asthma is a chronic respiratory disease characterized by airway inflammation and airway hyperresponsiveness (AHR). One strategy to treat allergic diseases is the development of new drugs. Flavonoids are compounds derived from plants and are known to have antiallergic, anti-inflammatory, and antioxidant properties. To investigate whether the flavonoid kaempferol glycoside 3-O-[beta-D-glycopiranosil-(1 -> 6)-alpha-L-ramnopiranosil]-7-O-alpha-L-ramnopiranosil-kaempferol (GRRK) would be capable of modulating allergic airway disease (AAD) either as a preventive (GRRK P) or curative (GRRK C) treatment in an experimental model of asthma. At weekly intervals, BALB/c mice were subcutaneously (sc) sensitized twice with ovalbumin (OVA)/alum and challenged twice with OVA administered intranasally. To evaluate any preventive effects GRRK was administered 1 h (hour) before each OVA-sensitization and challenge, while to analyze the curative effects mice were first sensitized with OVA, followed by GRRK given at day 18 through 21. The onset: of AAD was evaluated 24 h after the last OVA challenge. Both treatments resulted in a dose-dependent reduction in total leukocyte and eosinophil counts in the bronchoalveolar lavage fluid (BAL). GRRK also decreased CD4(+), B220(+), MHC class II and CD40 molecule expressions in BAL cells. Histology and lung mechanic showed that GRRK suppressed mucus production and ameliorated the AHR induced by OVA challenge. Furthermore, GRRK impaired Th2 cytokine production (IL-5 and IL-13) and did not induce a Th1 pattern of inflammation. These findings demonstrate that GRRK treatment before or after established allergic lung disease down-regulates key asthmatic features. Therefore. GRRK has a potential clinical use for the treatment of allergic asthma. (C) 2009 Elsevier B.V. All rights reserved.

Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)

Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq)

Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)

Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)

Identificador

INTERNATIONAL IMMUNOPHARMACOLOGY, v.9, n.13-14, p.1540-1548, 2009

1567-5769

http://producao.usp.br/handle/BDPI/28705

10.1016/j.intimp.2009.09.005

http://dx.doi.org/10.1016/j.intimp.2009.09.005

Idioma(s)

eng

Publicador

ELSEVIER SCIENCE BV

Relação

International Immunopharmacology

Direitos

restrictedAccess

Copyright ELSEVIER SCIENCE BV

Palavras-Chave #Flavonoid #Kaempferol glycoside #Ovalbumin #Airway hyperresponsiveness #Airway inflammation #ACTIVATED HUMAN BASOPHILS #MURINE ASTHMA MODEL #INFLAMMATORY RESPONSE #CYTOKINE PRODUCTION #MAST-CELLS #FLAVONOIDS #MICE #LUNG #HYPERREACTIVITY #INTERLEUKIN-5 #Immunology #Pharmacology & Pharmacy
Tipo

article

original article

publishedVersion